Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel treatment for Alzheimer's disease targeting toxic soluble amyloid beta oligomers, has scheduled its fourth quarter and year-end 2024 financial results announcement for March 27, 2025.
The company will host a conference call and live audio webcast at 8:00 a.m. ET to discuss business updates and financial performance. Interested participants must pre-register at least one day in advance to receive dial-in numbers and PIN. The webcast will remain accessible for a minimum of 30 days through the Investors section of Acumen's website.
Acumen Pharmaceuticals (NASDAQ: ABOS), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di un nuovo trattamento per la malattia di Alzheimer che mira agli oligomeri tossici solubili dell'amiloide beta, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'anno 2024 per il 27 marzo 2025.
L'azienda ospiterà una conferenza telefonica e una diretta audio alle 8:00 a.m. ET per discutere aggiornamenti aziendali e performance finanziaria. I partecipanti interessati devono registrarsi in anticipo almeno un giorno prima per ricevere i numeri di accesso e il PIN. La diretta rimarrà accessibile per un minimo di 30 giorni nella sezione Investitori del sito web di Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS), una empresa biofarmacéutica en etapa clínica centrada en desarrollar un nuevo tratamiento para la enfermedad de Alzheimer dirigido a los oligómeros de beta amiloide solubles y tóxicos, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año 2024 para el 27 de marzo de 2025.
La empresa llevará a cabo una conferencia telefónica y una transmisión de audio en vivo a las 8:00 a.m. ET para discutir actualizaciones comerciales y el desempeño financiero. Los participantes interesados deben registrarse con al menos un día de antelación para recibir los números de acceso y el PIN. La transmisión estará disponible durante un mínimo de 30 días en la sección de Inversores del sitio web de Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 독성 용해성 아밀로이드 베타 올리고머를 목표로 하는 알츠하이머병의 새로운 치료법 개발에 집중하는 임상 단계의 생명공학 회사로, 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 27일로 예정했습니다.
회사는 동부 표준시 8:00 a.m.에 비즈니스 업데이트 및 재무 성과에 대해 논의하기 위해 컨퍼런스 콜 및 실시간 오디오 웹캐스트를 개최합니다. 관심 있는 참가자는 최소 하루 전에 사전 등록해야 전화 접속 번호와 PIN을 받을 수 있습니다. 웹캐스트는 Acumen 웹사이트의 투자자 섹션을 통해 최소 30일 동안 접근 가능합니다.
Acumen Pharmaceuticals (NASDAQ: ABOS), une entreprise biopharmaceutique en phase clinique axée sur le développement d'un nouveau traitement de la maladie d'Alzheimer ciblant les oligomères amyloïdes bêta solubles et toxiques, a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année 2024 pour le 27 mars 2025.
L'entreprise organisera une conférence téléphonique et un webinaire audio en direct à 8h00 ET pour discuter des mises à jour commerciales et des performances financières. Les participants intéressés doivent s'inscrire au moins un jour à l'avance pour recevoir les numéros d'appel et le code PIN. Le webinaire restera accessible pendant un minimum de 30 jours dans la section Investisseurs du site web d'Acumen.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung einer neuartigen Behandlung der Alzheimer-Krankheit konzentriert, die auf toxische lösliche Amyloid-Beta-Oligomere abzielt, hat die Bekanntgabe seiner finanziellen Ergebnisse für das vierte Quartal und das Jahr 2024 auf den 27. März 2025 terminiert.
Das Unternehmen wird um 8:00 Uhr ET eine Telefonkonferenz und einen Live-Audio-Webcast veranstalten, um Geschäftsnachrichten und die finanzielle Leistung zu besprechen. Interessierte Teilnehmer müssen sich mindestens einen Tag im Voraus registrieren, um die Einwahlnummern und den PIN zu erhalten. Der Webcast wird für mindestens 30 Tage über den Bereich Investoren auf der Website von Acumen zugänglich sein.
- None.
- None.
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals (ABOS) release its Q4 and full-year 2024 earnings?
How can investors join ABOS's Q4 2024 earnings call?
Where can investors access ABOS's Q4 2024 earnings webcast replay?
What is the main therapeutic focus of Acumen Pharmaceuticals (ABOS)?
